If ctDNA reveals ERBB2 CNG discordant from a prior HER2-negative tissue IHC/FISH, it may prompt consideration of a new biopsy and/or use of HER2 therapy as the discordance may be a result of HER2 heterogeneity or tumor evolution rather than assay variability. The gene discussed is ERBB2; the disease is neoplasm.